Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent

ALPHARETTA, Ga., March 01, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 15/001,610 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”

Once the administrative process is complete, the U.S. Patent that issues from this application will provide intellectual property protection for methods of treating the posterior ocular disorder  Uveitis by non-surgically administering the corticosteroid triamcinolone acetonide to the suprachoroidal space of the eye. This patent represents one in a series of filings protecting the use of the suprachoroidal space as a location in the eye to dose drug that provides for higher bioavailability to target retinal and choroidal diseases and retains drug away from the anterior segment where side effects may occur, regardless of the method of administration.

Suprachoroidally administered CLS-TA, Clearside’s proprietary suspension formulation of triamcinolone acetonide, used either alone or together with an intravitreal anti-VEGF agent, is part of the Company’s pipeline for the treatments of unmet or underserved blinding eye diseases where the pathologies manifest in the choroid or retina.

“This, the ninth patent allowance in the United States related to our proprietary approach for the treatment of blinding diseases, represents another important addition to our intellectual property estate,” commented Clearside’s Chief Executive Officer and President, Daniel H. White.  “As we continue to advance our late-stage development programs for CLS-TA, a core component of our growth strategy is to ensure that the corresponding potential market opportunities are well protected.”

About Clearside

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing therapies for eye diseases using a proprietary treatment approach offering high access for the pharmacological candidates to the back of the eye through suprachoroidal injection. This new treatment paradigm offers potentially meaningful therapeutic benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion and diabetic macular edema. To learn more about how Clearside seeks to change ophthalmology treatment, please visit us at www.clearsidebio.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding Clearside’s intellectual property protection and the clinical development of, and the potential market for, Clearside’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 14, 2016 and Clearside’s other Periodic Reports filed with the SEC.  Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Stephen Kilmer
Investor Relations
(678) 270-3631
[email protected]

Charles Deignan
Chief Financial Officer
678-270-4005
[email protected]